Real World Exposure-Response Relationship of Vedolizumab in Inflammatory Bowel Disease: A Pooled Multicenter Observational Cohort Analysis of Clinical and Modeled Pharmacological Data

被引：0
|
作者：
Vande Casteele, Niels [1 ]
Sandborn, William J. [1 ]
Feagan, Brian G. [2 ,3 ,4 ]
Vermeire, Severine [5 ]
Dulai, Parambir S. [1 ]
Panes, Julian [6 ]
Yarur, Andres [7 ]
Roblin, Xavier [8 ]
Ben-Horin, Shomron [9 ,10 ]
Dotan, Iris [11 ]
Osterman, Mark [12 ]
Lindner, Dirk [13 ]
Agboton, Christian [13 ]
Rosario, Maria [14 ]
Osborn, Teresa [15 ]
机构：
[1] Univ Calif San Diego, La Jolla, CA 92093 USA
[2] Robarts Clin Trials Inc, Amsterdam, Netherlands
[3] Acad Med Ctr, Amsterdam, Netherlands
[4] Western Univ, London, ON, Canada
[5] Univ Hosp Leuven, Leuven, Vlaams Brabant, Belgium
[6] Hosp Clin Barcelona, IDIBAPS, CIBERehd, Barcelona, Catalonia, Spain
[7] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[8] Ctr Hosp Univ St Etienne, St Etienne, Auvergne, France
[9] Sheba Med Ctr, Tel Hashomer, Israel
[10] Tel Aviv Univ, Tel Aviv, Israel
[11] Rabin Med Ctr, Tel Aviv, Israel
[12] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA
[13] Takeda, Zurich, Switzerland
[14] Takeda, Cambridge, MA USA
[15] Takeda, Chicago, IL USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2020年 / 115卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S0652
引用
收藏
页码：S327 / S327
页数：1
相关论文
共 50 条
  • [41] Obesity and Response to Infliximab in Patients with Inflammatory Bowel Diseases: Pooled Analysis of Individual Participant Data from Clinical Trials
    Singh, Siddharth
    Proudfoot, James
    Xu, Ronghui
    Sandborn, William J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 (06): : 883 - 889
  • [42] Clinical characteristics of patients with Crohn's disease or ulcerative colitis treated with vedolizumab: a real-world data analysis
    Liang, H.
    Manne, S.
    Shick, J.
    Yu, S.
    Fusco, G.
    Dolin, P.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S466 - S467
  • [43] Clinical Characteristics of Patients With Crohn's Disease or Ulcerative Colitis Treated With Vedolizumab - A Real-World Data Analysis
    Liang, Huifang
    Manne, Sudhakar
    Shick, Jesse
    Yu, Shawn
    Fusco, Gregory
    Dolin, Paul
    GASTROENTEROLOGY, 2016, 150 (04) : S789 - S789
  • [44] Comparative Effectiveness of Vedolizumab vs. Infliximab Induction Therapy in Ulcerative Colitis: Experience of a Real-World Cohort at a Tertiary Inflammatory Bowel Disease Center
    Allamneni, Chaitanya
    Venkata, Krishna
    Yun, Huifeng
    Xie, Fenglong
    DeLoach, Lindsey
    Malik, Talha A.
    GASTROENTEROLOGY RESEARCH, 2018, 11 (01) : 41 - 45
  • [45] Effectiveness of vedolizumab on intestinal outcomes and articular manifestations: Real-world data from the Sicilian Network for inflammatory bowel disease (SN-IBD)
    Macaluso, F. S.
    Orlando, R.
    Fries, W.
    Scolaro, M.
    Magnano, A.
    Pluchino, D.
    Cappello, M.
    Morreale, G. C.
    Siringo, S.
    Privitera, A. C.
    Ferracane, C.
    Belluardo, N.
    Alberghina, N.
    Ventimiglia, M.
    Rizzuto, G.
    Renna, S.
    Cottone, M.
    Orlando, A.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S436 - S437
  • [46] Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis
    Peeyush Kumar
    Sudheer K. Vuyyuru
    Bhaskar Kante
    Saurabh Kedia
    Pabitra Sahu
    Mukesh Kumar Ranjan
    Sandeep Mundhra
    Rithvik Golla
    Mukesh Kumar
    Shubi Virmani
    Anvita Gupta
    Nidhi Yadav
    Govind Makharia
    Vineet Ahuja
    Indian Journal of Gastroenterology, 2022, 41 : 446 - 455
  • [47] Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis
    Kumar, Peeyush
    Vuyyuru, Sudheer K.
    Kante, Bhaskar
    Kedia, Saurabh
    Sahu, Pabitra
    Ranjan, Mukesh Kumar
    Mundhra, Sandeep
    Golla, Rithvik
    Kumar, Mukesh
    Virmani, Shubi
    Gupta, Anvita
    Yadav, Nidhi
    Makharia, Govind
    Ahuja, Vineet
    INDIAN JOURNAL OF GASTROENTEROLOGY, 2022, 41 (05) : 446 - 455
  • [48] Efficacy and safety of canakinumab in patients with Still's disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups
    Feist, Eugen
    Quartier, Pierre
    Fautrel, Bruno
    Schneider, Rayfel
    Sfriso, Paolo
    Efthimiou, Petros
    Cantarini, Luca
    Lheritier, Karine
    Leon, Karolynn
    Karyekar, Chetan S.
    Speziale, Antonio
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (04) : 668 - 675
  • [49] Clinical outcomes of vedolizumab maintenance treatment for Korean patients with inflammatory bowel disease who failed anti-TNF therapy: A KASID prospective multicenter cohort study
    Oh, K.
    Kim, J.
    Kim, N.
    Yoon, H.
    Lee, K. M.
    Park, D. I.
    Choi, C. H.
    Lee, C. K.
    Eun, C. S.
    Kang, S. B.
    Kim, E. S.
    Kim, Y. S.
    Jung, S. A.
    Jung, Y.
    Kim, T. O.
    Park, S. J.
    Im, J. P.
    Seo, G. S.
    Ye, B. D.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S523 - S524
  • [50] CLINICAL RESPONSE, EFFECTIVENESS, SAFETY AND MUCOSAL HEALING INDUCTION OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: A PRELIMINARY REAL-LIFE MULTICENTRIC EXPERIENCE IN SOUTHERN ITALY
    Contaldo, A.
    Losurdo, G.
    Bossa, F.
    Biscaglia, G.
    Mazzuoli, S.
    Fanigliulo, L.
    Tursi, A.
    Lovero, R.
    Ierardi, E.
    Principi, M. B.
    Di Leo, A.
    DIGESTIVE AND LIVER DISEASE, 2018, 50 (02) : E198 - E198
12345